In a report released today, Adam Maeder from Piper Sandler reiterated a Buy rating on Neuronetics (STIM – Research Report), with a price target of $8.00. The company’s shares closed yesterday at $3.22.
According to TipRanks, Maeder is a 5-star analyst with an average return of 20.7% and a 58.05% success rate. Maeder covers the Healthcare sector, focusing on stocks such as Inari Medical, Inspire Medical Systems, and Nyxoah.
Neuronetics has an analyst consensus of Strong Buy, with a price target consensus of $7.00, an 117.39% upside from current levels. In a report released today, JMP Securities also reiterated a Buy rating on the stock with a $7.00 price target.
See today’s best-performing stocks on TipRanks >>
The company has a one-year high of $4.76 and a one-year low of $1.03. Currently, Neuronetics has an average volume of 219.4K.
Based on the recent corporate insider activity of 36 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of STIM in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Neuronetics (STIM) Company Description:
Neuronetics, Inc. commercial stage medical technology company. It focuses on designing, developing and marketing products for the patients suffering from psychiatric disorders. The firm offers NeuroStar TMS, a therapy system for the treatment of major depressive disorders in adult patients. It also provides a range of support services, including patient education, practice data management system, and customer and technical services to help the client start and manage TMS therapy systems. The company was founded by Steven B. Waite, Bruce J. Shook, Norman R. Weldon and Thomas D. Weldon in April 2003 and is headquartered in Malvern, PA.
Read More on STIM:
- Neuronetics Inc Shares New Investor Insights Online
- Neuronetics Reports Record Fourth Quarter and Record Full Year 2023 Financial and Operating Results
- Is STIM a Buy, Before Earnings?
- Neuronetics to Report Fourth Quarter 2023 Financial and Operating Results and Host Conference Call
- Neuronetics Launches Latest Evolution in its TrakStar® Patient Data Management System
